Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

"God knows what volume they're actually selling. And who knows? You're just taking it," one expert told The Post.

Eli Lilly 's (NYSE: LLY) stock is up by more than 736% over the last five years, largely thanks to its best-selling medicines for type 2 diabetes and obesity. And while it likely has plenty of upside ...

The new funding will bring the Indianapolis-based drugmaker’s total investment in the Lebanon site to more than $13 billion, ...

Cramer remains steadfast on Eli Lilly and Company (NYSE:LLY) as per Mad Money’s episode on September 30. Despite there being ...

In this article, we will discuss: 12 Best Growth Stocks To Buy According To Hedge Funds.

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The effectiveness can vary based on the individual response and adherence to treatment. Research indicates that GLP-1 ...